CCL11 and allergic asthma: Indeed, anti-eotaxin-1 and eosinophil-depleting agents, such as humanized anti-IL-5 receptor antibodies and anti-Siglec-8 molecules, are currently being developed to treat eosinophilic disorders such as allergic asthma (9, 61–66), and one has to keep in mind the possibility that such drugs may disrupt tissue homeostasis by preventing organ-specific homing of hEos or by affecting their survival or functions.